Sichuan Hezong Medicine Easy-to-buy Pharmaceutical Co., Ltd. (SHE:300937)
China
· Delayed Price · Currency is CNY 28.55
+0.66 (2.37%)
At close: Apr 29, 2026
SHE:300937 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 | 2021 - 2017 |
| Operating Revenue | 4,454 | 4,348 | 4,407 | 3,946 | 3,384 | Upgrade
|
| Other Revenue | - | 32.87 | 23.54 | 23.65 | 16.23 | Upgrade
|
| Revenue | 4,454 | 4,381 | 4,430 | 3,969 | 3,401 | Upgrade
|
| Revenue Growth (YoY) | 1.67% | -1.12% | 11.62% | 16.72% | 21.88% | Upgrade
|
| Cost of Revenue | 3,990 | 4,001 | 4,073 | 3,663 | 3,219 | Upgrade
|
| Gross Profit | 463.91 | 379.82 | 357.85 | 306.05 | 181.48 | Upgrade
|
| Selling, General & Admin | 401.79 | 321.89 | 247.44 | 218.86 | 164.5 | Upgrade
|
| Research & Development | 10.72 | 15.47 | 19.32 | 17.71 | 11.38 | Upgrade
|
| Other Operating Expenses | 7.15 | 7.21 | 7.4 | 6.47 | 5.11 | Upgrade
|
| Operating Expenses | 419.66 | 350.66 | 283.89 | 247.86 | 181.44 | Upgrade
|
| Operating Income | 44.25 | 29.16 | 73.97 | 58.19 | 0.04 | Upgrade
|
| Interest Expense | - | -9.71 | -6.58 | -6.42 | -1.82 | Upgrade
|
| Interest & Investment Income | - | 3.87 | 3.81 | 2.38 | 9.65 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 0 | -0 | -0 | - | Upgrade
|
| Other Non Operating Income (Expenses) | -26.78 | -4.66 | -6.17 | -10.31 | -3.94 | Upgrade
|
| EBT Excluding Unusual Items | 17.46 | 18.66 | 65.02 | 43.83 | 3.93 | Upgrade
|
| Impairment of Goodwill | - | - | - | -1.62 | - | Upgrade
|
| Gain (Loss) on Sale of Investments | -0.36 | -1.84 | - | -4.29 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.01 | -0.61 | -0.05 | -0.08 | -0.11 | Upgrade
|
| Asset Writedown | -9.91 | 0.4 | -0.01 | -0.11 | -0 | Upgrade
|
| Other Unusual Items | - | 0.56 | 4.92 | 7.16 | 4.3 | Upgrade
|
| Pretax Income | 7.18 | 17.18 | 69.88 | 44.89 | 8.12 | Upgrade
|
| Income Tax Expense | 23.63 | 1.78 | 13.11 | 8.75 | 1.4 | Upgrade
|
| Earnings From Continuing Operations | -16.46 | 15.4 | 56.77 | 36.14 | 6.73 | Upgrade
|
| Minority Interest in Earnings | 3.6 | 0.96 | 2.76 | 5.88 | -0.33 | Upgrade
|
| Net Income | -12.85 | 16.36 | 59.53 | 42.02 | 6.4 | Upgrade
|
| Net Income to Common | -12.85 | 16.36 | 59.53 | 42.02 | 6.4 | Upgrade
|
| Net Income Growth | - | -72.52% | 41.69% | 556.48% | -88.15% | Upgrade
|
| Shares Outstanding (Basic) | 96 | 96 | 96 | 95 | 91 | Upgrade
|
| Shares Outstanding (Diluted) | 96 | 96 | 96 | 95 | 91 | Upgrade
|
| Shares Change (YoY) | -0.55% | 0.21% | 0.56% | 4.44% | 26.94% | Upgrade
|
| EPS (Basic) | -0.13 | 0.17 | 0.62 | 0.44 | 0.07 | Upgrade
|
| EPS (Diluted) | -0.13 | 0.17 | 0.62 | 0.44 | 0.07 | Upgrade
|
| EPS Growth | - | -72.58% | 40.91% | 528.57% | -90.67% | Upgrade
|
| Free Cash Flow | -20.8 | 95.48 | -150.8 | 134.35 | -185.81 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | 0.99 | -1.57 | 1.41 | -2.03 | Upgrade
|
| Dividend Per Share | - | 0.100 | 0.220 | 0.200 | - | Upgrade
|
| Dividend Growth | - | -54.55% | 10.00% | - | - | Upgrade
|
| Gross Margin | 10.42% | 8.67% | 8.08% | 7.71% | 5.34% | Upgrade
|
| Operating Margin | 0.99% | 0.67% | 1.67% | 1.47% | 0.00% | Upgrade
|
| Profit Margin | -0.29% | 0.37% | 1.34% | 1.06% | 0.19% | Upgrade
|
| Free Cash Flow Margin | -0.47% | 2.18% | -3.40% | 3.38% | -5.46% | Upgrade
|
| EBITDA | 65.54 | 48.37 | 93.03 | 77.46 | 13.37 | Upgrade
|
| EBITDA Margin | 1.47% | 1.10% | 2.10% | 1.95% | 0.39% | Upgrade
|
| D&A For EBITDA | 21.3 | 19.21 | 19.06 | 19.27 | 13.33 | Upgrade
|
| EBIT | 44.25 | 29.16 | 73.97 | 58.19 | 0.04 | Upgrade
|
| EBIT Margin | 0.99% | 0.67% | 1.67% | 1.47% | 0.00% | Upgrade
|
| Effective Tax Rate | 329.27% | 10.34% | 18.76% | 19.50% | 17.17% | Upgrade
|
| Revenue as Reported | - | - | - | 3,969 | 3,401 | Upgrade
|
| Advertising Expenses | - | 76.51 | 36.27 | 28.48 | 19.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.